CN101945670B - 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统 - Google Patents

用于水溶性阳离子两亲性药用活性物质给药的药物递送系统 Download PDF

Info

Publication number
CN101945670B
CN101945670B CN2008801270176A CN200880127017A CN101945670B CN 101945670 B CN101945670 B CN 101945670B CN 2008801270176 A CN2008801270176 A CN 2008801270176A CN 200880127017 A CN200880127017 A CN 200880127017A CN 101945670 B CN101945670 B CN 101945670B
Authority
CN
China
Prior art keywords
sodium salt
acthiol
acyl group
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801270176A
Other languages
English (en)
Chinese (zh)
Other versions
CN101945670A (zh
Inventor
朱莉安·阿列克索夫
伊戈尔·洛科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oswald Mia Pharmaceutical Co
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of CN101945670A publication Critical patent/CN101945670A/zh
Application granted granted Critical
Publication of CN101945670B publication Critical patent/CN101945670B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801270176A 2007-12-19 2008-12-18 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统 Expired - Fee Related CN101945670B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SEPCT/SE2007/001129 2007-12-19
PCT/SE2007/001129 WO2009078756A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PCT/SE2008/051516 WO2009078803A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Publications (2)

Publication Number Publication Date
CN101945670A CN101945670A (zh) 2011-01-12
CN101945670B true CN101945670B (zh) 2012-08-22

Family

ID=40795734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801270176A Expired - Fee Related CN101945670B (zh) 2007-12-19 2008-12-18 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统

Country Status (12)

Country Link
US (1) US8765173B2 (https=)
EP (1) EP2231192B1 (https=)
JP (1) JP5466173B2 (https=)
KR (1) KR101616134B1 (https=)
CN (1) CN101945670B (https=)
AU (1) AU2008339100B2 (https=)
BR (1) BRPI0821741B8 (https=)
CA (1) CA2709267C (https=)
EA (1) EA018636B1 (https=)
MX (1) MX2010006907A (https=)
NZ (1) NZ586853A (https=)
WO (2) WO2009078756A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
CN102008444B (zh) * 2010-11-26 2012-06-20 北京工业大学 载有米托蒽醌的葡聚糖-聚乳酸共聚物纳米粒子的制备方法
CA2958820A1 (en) 2014-09-10 2016-03-17 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs
CN112321465B (zh) * 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358420C (en) * 1999-03-11 2010-03-16 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US20050249786A1 (en) 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005089106A2 (en) * 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
EP2207803B1 (en) * 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arsenov D. V. et al.Synthesis of N-(all-trans-retionyl)dexorubicin and study of the antitumor activity of its complex with blood serum proteins.《Pharmaceutical Chemistry Journal》.2001,第35卷(第4期),186-189. *

Also Published As

Publication number Publication date
AU2008339100A1 (en) 2009-06-25
CN101945670A (zh) 2011-01-12
WO2009078756A1 (en) 2009-06-25
MX2010006907A (es) 2010-11-10
CA2709267C (en) 2016-02-09
NZ586853A (en) 2012-06-29
JP2011507839A (ja) 2011-03-10
CA2709267A1 (en) 2009-06-25
BRPI0821741B1 (pt) 2020-11-17
US20110123607A1 (en) 2011-05-26
BRPI0821741A2 (pt) 2015-06-16
AU2008339100B2 (en) 2015-08-27
EP2231192A1 (en) 2010-09-29
EP2231192B1 (en) 2017-08-02
WO2009078803A1 (en) 2009-06-25
EA018636B1 (ru) 2013-09-30
KR101616134B1 (ko) 2016-04-27
BRPI0821741B8 (pt) 2021-05-25
JP5466173B2 (ja) 2014-04-09
EA201070625A1 (ru) 2010-12-30
EP2231192A4 (en) 2014-12-03
US8765173B2 (en) 2014-07-01
KR20100103588A (ko) 2010-09-27

Similar Documents

Publication Publication Date Title
Tang et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
CN101951956B (zh) 用于水溶性差的药用活性物质给药的药物递送系统
US20190015335A1 (en) Hepatoprotective particles and systems and methods of use thereof
CN101945670B (zh) 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统
CN103040757A (zh) 核-壳型纳米药物颗粒、其制备方法及应用
CN110721318B (zh) 一种双硫仑纳米颗粒及其制备方法和用途
CN102370622A (zh) 一种载药物纳米粒及其制备方法和应用
Wang et al. Nano-porous silica aerogels as promising biomaterials for oral drug delivery of paclitaxel
WO2016015522A1 (zh) 脂肪酸结合型白蛋白-药物纳米粒子冻干制剂及制备方法
CN101945671B (zh) 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统
CN102552154A (zh) 蒽环类抗肿瘤抗生素油酸复合物的白蛋白纳米粒制剂
CN107137350A (zh) 一种紫杉醇聚合物胶束及其制备方法
CN109718202B (zh) 一种适用于载疏水性化学药物的靶向载药胶束
CN103432083A (zh) 一种甘草酸介导的羟基喜树碱白蛋白肝癌靶向纳米粒冻干粉的制备工艺
Yi et al. Mitochondria-Targeting-Based of Paclitaxel-Loaded Triphenylphosphine-Pluronic F127-Hyaluronic Acid Nanomicelles in Multi-Drug Resistant Hepatocellular Carcinoma
CN109464382B (zh) 一种可注射的高载药量的紫杉醇凝胶及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210429

Address after: uppsala

Patentee after: Oswald MIA pharmaceutical Co.

Address before: London, England

Patentee before: ARDENIA INVESTMENTS, Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822